A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Study sponsor: Ocular Therapeutix, Inc. · OCUL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-03Estimated
Enrollment · participants930Estimated
Source updated2026-03-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.